- Home
- JLS vs DTIL Comparison
JLS vs DTIL Comparison
Compare JLS & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLS | DTIL |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.9M | 97.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | JLS | DTIL |
|---|---|---|
| Price | $18.45 | $3.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 19.6K | ★ 151.7K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | N/A | ★ 106.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.80 | $3.53 |
| 52 Week High | $19.25 | $8.82 |
Technical Indicators
Market Signals| Indicator | JLS | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 49.45 |
| Support Level | $18.37 | $3.64 |
| Resistance Level | $18.48 | $4.11 |
| Average True Range (ATR) | 0.14 | 0.23 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 12.26 | 66.94 |
Price Performance
Historical ComparisonAbout JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.